下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEWortmanninCat. No.: HY-10197CAS No.: 19545-26-7Synonyms: SL-2052; KY-12420分式: CHO分量: 428.43作靶點(diǎn): PI3K; ATM/ATR; DNA-PK; Polo-like Kinase (PLK)作通路: PI3K/Akt/mTOR; Cell Cycle/DNA Damage儲存式: Powder -20C 3 years4C 2 yearsIn solvent -
2、80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (116.71 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.3341 mL 11.6705 mL 23.3410 mL5 mM 0.4668 mL 2.3341 mL 4.6682 mL10 mM 0.2334 mL 1.1671 mL 2.3341 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗
3、請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄清的儲備液,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (4.85 mM); Suspended solution; Need ultrasonic2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Sol
4、ubility: 2.08 mg/mL (4.85 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (4.85 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Wortmannin種多靶點(diǎn)抑制劑。Wortmannin 抑制 PI3K 1,MLCK 1,DNA-PK 2,ATM 2,ATR 2和 Polo-like kinase 3 (Plk3 3),IC50
5、 分別為 3 nM,200 nM,16 nM,150 nM,1.8 M 和 48 nM。IC50 & Target PI3K DNA-PK PLK3 ATM3 nM (IC50) 16 nM (IC50) 48 nM (IC50) 150 nM (IC50)ATR MLCK1.8 M (IC50) 200 nM (IC50)體外研究 Wortmannin (0-100 nM; 24-72 hours) inhibits the proliferation of K562 cells in a time- and dose-dependentmanner. The IC50 values at
6、24 hour, 48 hour, and 72 hour are 250.10 nM, 12.50.08 nM, and 6.250.11nM, respectively 4.Cell Proliferation Assay 4Cell Line: K562 cellsConcentration: 0, 6.25, 12.5, 25, 50 and 100 nMIncubation Time: 0, 24, 48 and 72 hoursResult: Inhibited the K562 cells proliferation. The IC50 value at 24 hour, 48
7、hour, and 72 hourwas 250.10 nM, 12.50.08 nM, and 6.250.11 nM.體內(nèi)研究Wortmannin (oral gavage; daily; in Scid mice; one group of eight mice is dosed with Wortmannin 1 mg/kg forall 14 days. The second group of eight mice is dosed with Wortmannin 1.5 mg/kg for the first 5 days and thedose is decreased to 1
8、 mg/kg for the remaining treatment period) treatment significantly slower the growthrate of murine C3H mammary tumor and human MCF-7 breast cancer xenograft. A dose of 1 mg/kgWortmannin for 7 days decrease the tumor burdens in mice with established murine C3H mammary tumorsby 54% relative to control
9、s. Human MCF-7 breast cancer xenograft burdens are decreased by 97% relativeto controls after 14 days of 1 mg/kg Wortmannin beginning 1 day after tumor implantation 5.Animal Model: Scid mice with the murine C3H mammary tumor or human MCF-7 breast cancerxenograft 5Dosage: 1 mg/kg and 1.5 mg/kgAdminis
10、tration: Oral gavage; daily; one group 1 mg/kg for 14 days; second group 1.5 mg/kg for 5 daysthen 1.0 mg/kg for 9 days.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEResult: The growth rate of the treated tumors was significantly slower during drug administrationthan that of nontreated tumors.戶使本產(chǎn)
11、品發(fā)表的科研獻(xiàn) Cell Mol Life Sci. 2018 Jul;75(14):2627-2641. Cell Death Dis. 2019 Aug. J Mol Med (Berl). 2019 Jun 14. Arthritis Res Ther. 2018 Feb 7;20(1):20. Oncol Rep. 2019 Jun 19.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Yano H, et al. Inhibition of histamine secretion by wor
12、tmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. JBiol Chem. 1993 Dec 5;268(34):25846-56.2. Sarkaria JN, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998Oct 1;58(19):4375-82.3. Liu Y, et al. Polo-
13、like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem. 2007 Jan 26;282(4):2505-11.4. Wu Q, et al. Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro. J Huazhong Univ Sci Technolog Med Sci.2009 Aug;29(4):451-6.5. Lemke LE, et al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitivephosphatidylinositol-3-kinase. Cancer Chemother Pharmacol. 1999;44(6):491-
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 博物館展覽與策展研究出版考核試卷
- 信息系統(tǒng)人力資源管理與優(yōu)化策略考核試卷
- 房顫抗凝藥物治療
- 冠心病的對癥治療
- 學(xué)校生命健康教育
- 前交叉韌帶下止點(diǎn)撕脫康復(fù)
- 腎結(jié)石腎積水護(hù)理小講課
- 投標(biāo)管理系統(tǒng)規(guī)章制度及流程
- 盈利與財務(wù)管理制度
- 公共衛(wèi)生與流行病防控制度
- 心理健康與大學(xué)生活學(xué)習(xí)通超星期末考試答案章節(jié)答案2024年
- 借款協(xié)議(父母借款給子女買房協(xié)議)(二篇)
- 國家開放大學(xué)電大本科《工程經(jīng)濟(jì)與管理》2023-2024期末試題及答案(試卷代號:1141)
- 歌唱語音智慧樹知到期末考試答案章節(jié)答案2024年齊魯師范學(xué)院
- 國開(甘肅)2024年春《地域文化(專)》形考任務(wù)1-4終考答案
- MOOC 美在民間-南京農(nóng)業(yè)大學(xué) 中國大學(xué)慕課答案
- 國家開放大學(xué)《Python語言基礎(chǔ)》實驗1:Python 基礎(chǔ)環(huán)境熟悉參考答案
- 《中國心力衰竭診斷和治療指南2024》解讀
- 中國馬克思主義與當(dāng)代課后習(xí)題答案
- 蹲踞式跳遠(yuǎn)教學(xué)課件
- 智能系統(tǒng)工程自評報告
評論
0/150
提交評論